Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial.

ABSTRACT: The management of advanced ovarian cancer has significantly developed with the integration of bevacizumab into standard therapeutic regimens. While the efficacy of bevacizumab has been established in trials such as GOG218, ICON7, and PAOLA-1, there remains a gap in understanding the advantages of the 7.5 mg/kg dose over the 15 mg/kg regimen. This study addresses this gap by evaluating the efficacy, safety, and cost effectiveness of these two dosing strategies, considering the heterogeneity of patient profiles, including BRCA mutation status and homologous recombination deficiency (HRD). This multicenter, randomized clinical trial will recruit patients with newly diagnosed, advanced-stage (FIGO III/IV) ovarian, fallopian tube, or primary peritoneal cancer. Participants will undergo three cy

SUBMITTER: Ostrowska-Lesko M 

PROVIDER: S-EPMC12400637 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature